This study investigates advanced pancreatic ductal adenocarcinoma. It evaluates the combination of investigational medication HRS-4642 and adebelimab.
The study focuses on understanding the safety, tolerability, and effectiveness of the treatment combination.
- Who can participate: Adults aged 18 to 75 with advanced pancreatic ductal adenocarcinoma may participate. Eligibility requires at least one measurable lesion and an ECOG Performance Status of 0 or 1.
- Study details: Participants will receive a combination of investigational medications. Some may receive a placebo, which is an inactive substance that looks like the investigational medicine but does not contain any medicine.